Shares of Spectrum Pharmaceuticals (SPPI -0.7%) slip after Credit Suisse initiated the shares...
Tuesday, January 15, 3:18 PM ETShares of Spectrum Pharmaceuticals (SPPI -0.7%) slip after Credit Suisse initiated the shares with a tepid Neutral rating ealier this morning. The firm says its concerned about the impact of increased competition from Leucovorin, which is a generic SPPI's Fusilev. Sales of Fusilev may decrease from 2012 highs and limit near-term stock performance, and Credit Suisse feels it's more prudent to take a wait-and-see approach and look to buy SPPI once there's greater visibility.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles